Aspire Biopharma Holdings (ASBP) Total Liabilities (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Total Liabilities of $3.2 million for Q1 2026, down 67.25% year-over-year from $9.9 million in Q1 2025, and down 57.75% quarter-over-quarter from $7.7 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Total Liabilities (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Total Liabilities for 6 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 67.25% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (down 67.25% YoY), while the FY2025 annual figure was $7.7 million, up 355.46% from the prior year.
- Total Liabilities declined to $3.2 million in Q1 2026 per ASBP's latest filing, from $7.7 million in the prior quarter.
- Across five years, Total Liabilities topped out at $13.9 million in Q3 2025 and bottomed at $284356.0 in Q2 2023.
- Historically, Total Liabilities has averaged $7.0 million across 5 years, with a median of $8.8 million in 2025.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 3684.81% — and 2023, when it sank 97.41%.
- Aspire Biopharma Holdings' Total Liabilities stood at $11.1 million in 2022, then slumped by 96.37% to $403328.0 in 2023, then jumped by 318.54% to $1.7 million in 2024, then soared by 355.46% to $7.7 million in 2025, then tumbled by 57.75% to $3.2 million in 2026.
- Business Quant data shows ASBP's Total Liabilities at $3.2 million in Q1 2026, $7.7 million in Q4 2025, and $13.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 1.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.78 Mn |
| Mar 31, 2026 | 3.25 Mn |
| Dec 31, 2025 | 7.69 Mn |
| Sep 30, 2025 | 13.87 Mn |
| Jun 30, 2025 | 10.61 Mn |
| Mar 31, 2025 | 9.92 Mn |
| Dec 31, 2024 | 1.69 Mn |
| Jun 30, 2024 | 6.24 Mn |
| Mar 31, 2024 | 2.63 Mn |
| Dec 31, 2023 | 403,328.00 |
| Sep 30, 2023 | 316,316.00 |
| Jun 30, 2023 | 284,356.00 |
| Mar 31, 2023 | 11.17 Mn |
| Dec 31, 2022 | 11.12 Mn |
| Sep 30, 2022 | 11.00 Mn |
| Jun 30, 2022 | 10.96 Mn |
| Mar 31, 2022 | 10.86 Mn |
| Dec 31, 2021 | 293,696.00 |